FB3002, a loxoprofen sodium hot-melt adhesive patch with loxoprofen sodium as the active ingredient, adopts a hot-melt adhesive patch formulation. It is mainly indicated for the treatment of musculoskeletal and joint pain and represents a new topical analgesic patch under the company’s key development pipeline. Compared with conventional rubber plasters, this product causes less skin irritation, carries a lower risk of allergic reactions, and has no pungent odor. It also features good adhesion and favorable skin conformability, enabling flexible application on movable joint sites. When compared with gel plasters, it delivers stronger adhesion and is less prone to detachment. The formulation is thinner and lighter, facilitating routine use by patients. FB3002 has now obtained the Drug Registration Certificate issued by the National Medical Products Administration (NMPA). Meanwhile, Qihe Frontier Biopharmaceutical Co., Ltd., the company’s wholly-owned subsidiary, has acquired the production license for this product, providing manufacturing capacity to support the subsequent commercial production and market supply of FB3002.